Virology & Mycology Infectious Diseases

Search :     Advanced Search 

HomeHome   |   Join Join   |   Contact Contact     

Journal of Pulmonary & Respiratory Medicine Video Journal of Pulmonary & Respiratory Medicine Linkedin - Journal of Pulmonary & Respiratory Medicine Twitter - Journal of Pulmonary & Respiratory Medicine Facebook - Journal of Pulmonary & Respiratory Medicine Journal of Pulmonary & Respiratory Medicine Blog
Open Access
1Sunovion Pharmaceuticals Inc. Marlborough, MA, USA Vamsi K Bollu1*, 1Sunovion Pharmaceuticals Inc. Marlborough, MA, USA John Karafilidis1, 2RTI Health Solutions, USA Ann Colosia2, 2RTI Health Solutions, USA Lee Bennett2 and 3Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, Texas, USA Nicola Hanania3
Corresponding Author : Vamsi Bollu
Sunovion Pharmaceuticals Inc. 84 Waterford Drive
Marlborough MA 01752, USA
Tel: 508-357-7704
Fax: 508-357-7662
Received January 15, 2013; Accepted February 01, 2013; Published February 04, 2013
Citation: Bollu VK, Karafilidis J, Colosia A, Bennett L, Hanania N (2013) Comparison of Efficacy and Safety Outcomes in Randomized Trials of Long- Acting and Short-Acting ?2-Agonists for Chronic Obstructive Pulmonary Disease: A Review. J Pulmon Resp Med 3:137. doi:
Copyright: © 2013 Bollu VK, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at
DownloadPubmed DownloadScholar Google
Pulmonary disease; Chronic obstructive; Adrenergic beta-agonists; Randomized controlled trials; Bronchodilators
COPD: Chronic Obstructive Pulmonary Disease; LABA: Long Acting Beta Agonist; SABA: Short Acting Beta Agonist; FEV1: Forced Expiratory Volume (in 1 second); BDI: Baseline Dyspnea Index; TDI: Transitional Dyspnea Index; SGRQ: St. George’s Respiratory Questionnaire; CRDQ: Chronic Respiratory Disease Questionnaire
Chronic Obstructive Pulmonary Disease (COPD) is a progressive disease affecting more than 24 million people in the United States [1,2]. It is the fourth-leading cause of death in the United States, with more than 121,000 deaths due to COPD reported in 2009 [3]. In 2002, the direct costs to treat COPD in the United States were estimated at $18 billion and this value has been projected to climb to $29.5 billion in 2010 [4]. Some of the burden of COPD is related to certain comorbid conditions such as cardiovascular disease, respiratory infections, and osteoporosis. In addition, COPD reduces quality of life by limiting the functional and exercise capacity of affected individuals.
Because no medications have been shown to alter the progression of COPD, the aims of current pharmacotherapy are to decrease symptoms, reduce the incidence and severity of exacerbations, and improve quality of life and exercise tolerance [5]. Inhaled bronchodilator medications constitute the cornerstone of symptom management in COPD. Inhaled β2-agonists work by activating the β2-adrenoceptor which relaxes the smooth muscle cells of airways. These agents are further classified based on duration of action into short-acting β2-agonists (SABAs) (e.g., levalbuterol, albuterol) and Long-Acting β2-Agonists (LABAs) (e.g., formoterol, arformoterol, indacaterol, and salmeterol). The duration of action for most SABAs is 4 to 6 hours (for levalbuterol, up to 8 hours for some patients), whereas the duration for LABAs is 12 or more hours.
For maintenance therapy in patients with moderate to severe COPD, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines recommend the use of long-acting bronchodilators (including LABAs) because they are effective and convenient [6]. However, research has shown that many patients do not receive maintenance therapies and primary care physicians are often unfamiliar with the guidelines [7,8]. Some physicians or payers may consider LABAs and SABAs to be functionally equivalent and interchangeable as maintenance therapies.
Randomized Controlled Trials (RCTs) of COPD treatments differ in study design depending on the outcome variables. For RCTS examining maintenance outcomes in COPD, the primary outcome variables are related to the prevention of exacerbations or altering disease progression. However, most COPD RCTsexamine improvement in airflow obstruction and symptom relief (chronic cough, excess sputum, and dyspnea). The Food and Drug Administration (FDA) in the United States has offered guidance on primary outcome measures and study durations depending on the indication sought for a COPD treatment. For studies measuring improvement in airflow, the recommended primary outcome variable is post-dose FEV1 (forced expiratory volume in 1 second) and the recommended study duration is 3 to 6 months. For studies assessing the prevention of exacerbations, whether based on severity, duration, frequency of exacerbations or time to first exacerbation, the recommended study duration is 1 year. Finally, for studies examining disease progression alteration the recommend outcome variable is the reduced trajectory of serial FEV1 measured over a 3-year period [9].
Although both SABAs and LABAs appear to be used for long-term treatment of COPD in usual clinical care [10], there have been no comprehensive reviews or meta-analyses comparing the use of LABAs versus SABAs for maintenance therapy. The objective of this study was to summarize the evidence for LABAs and SABAs in maintenance management of patients with COPD based on available published RCTs. This review examined RCTs of LABAs and SABAs in patients with stable COPD to compare their effects on lung function (FEV1), incidence of exacerbations, and use of rescue medications, β-mediated adverse events, and symptoms such as dyspnea and exercise-tolerance measures.
The focus of this review was published, RCTs involving adult patients with stable COPD without asthma who received a LABA or a SABA either alone or combined with other therapies. The outcomes of interest were lung function as measured by FEV1, incidence of exacerbations, use of rescue medications, dyspnea, exercise tolerance, quality of life, and β-mediated adverse events (especially cardiovascular events).
A systematic literature search was conducted using PubMed/ Medline, Embase, and the Cochrane Library to identify relevant studies published and indexed between January 1, 1990 and July 16, 2010. Multiple search terms were used and the reference sections in other literature reviews or meta-analyses were examined to identify additional studies. Maintenance therapy was broadly defined as 2 or more weeks of regular dosing of a LABA or SABA; studies with durations of less than 2 weeks were excluded. Based on a preliminary review of the literature, few direct comparative studies of SABAs versus LABAs were expected and the most common comparators for indirect meta-analysis were placebo and ipratropium. Studies that did not directly compare a LABA versus a SABA or compare a LABA or SABA with placebo or ipratropium were excluded.
Data abstraction was performed by a single investigator using a prespecified extraction form. The following information was abstracted from each study: (1) author identification, (2) year of publication, (3) study design (parallel or crossover) and quality, (4) sample size, (5) key inclusion criteria and exclusion criteria, (6) drug and dosing for each treatment arm, and (7) baseline characteristics (mean age, gender, and predose FEV1/forced vital capacity [FVC]). The quality assessment examined the blinding of patients, care providers, and outcome assessors; similarity of treatment groups at baseline; imbalances between treatment groups in dropout rates; completion rates; whether the analysis was on the intention-to-treat patient set; how missing data were addressed; and selective reporting of outcomes [11].
For each outcome of interest, abstracted data included the outcome definition, the analysis time point, sample size, and reported summary measures (e.g., mean, standard deviation). For the outcomes with highly variable definitions, such as FEV1, Area Under the Curve (AUC), and rescue medication use, we extracted values for a broad range of definitions. Other outcomes extracted included: exercise tolerance and related dyspnea scores on the Borg scale [12]; dyspnea as measured by Baseline Dyspnea Index (BDI) and Transitional Dyspnea Index (TDI) [13]; incidence of exacerbations; quality of life assessments measured by the St. George’s Respiratory Questionnaire (SGRQ) [14] or the Chronic Respiratory Disease Questionnaire (CRDQ) [15]; and incidence of beta-mediated adverse events, cardiac adverse events, and metabolic abnormalities.
The initial search yielded 938 studies. Following abstract review, 873 studies were excluded based on criteria specified in the study protocol (Figure 1). Full-text review of the remaining 65 studies resulted in 3 additional exclusions, leaving 62 studies for data extraction. Among these 62 studies, only one study directly evaluated a SABA versus a LABA [16], 49 studies evaluated a LABA versus placebo or ipratropium [17-65], and12 evaluated a SABA versus placebo or ipratropium [66-77]. There was insufficient data to complete a direct meta-analysis of SABA versus LABA. Due to the variations in outcomes and definitions and the small number of SABA studies, there was also insufficient data to allow meaningful indirect comparisons of LABAs and SABAs on the extracted endpoints. Below is a description of the limitations for FEV1 and exacerbations, which were the most common outcome variables. A brief summary follows for other outcome variables.
Thirty-one studies reported numerical FEV1 outcomes [20,22-24,26,27,29,30,33-36,38-40,42,44-46,48,49,51,56,58,59,61,63,66,67,72-77], but only 17 studies reported change in peak FEV1 (occurring within 1-4 hours after dosing) from baseline [16,27,34-36,40,44,45,48,58,63,66,67,70,74,77]. None of these 17 studies included an analysis of a LABA versus ipratropium, eliminating the possibility of an indirect comparison through ipratropium. Among the placebocontrolled studies, 10 LABA [34-36,45,48,58,63] studies and 5 SABA studies [66,67,74,75,77] reported change in peak FEV1, but only 2 of the SABA studies (both 2-weeks in duration) reported the variance for the outcome variable. Similarly, for serial measurements of FEV1 after bronchodilator administration, there was only a single placebo controlled SABA study [69].
Definitions for the incidence of exacerbations varied across the 35 studies reporting this outcome [16,19-21,23-30,32-34,37,41,43,47,49,50,52,56,58-60,62,64,66-70,74,76]. However, 33 studies included definitions of exacerbations that were moderate to severe based on the requirement for a change in the baseline medication regimen to improve respiration [16,19-21,23-30,32-34,37,41,43,47,49,50,52,58-60,62,64,66-70,74]. Among the 27 studies reporting the percentage of patients experiencing exacerbations: 21 studies evaluated LABA therapy versus placebo [19-21,23,27,29,30,32-34,37,41,43,47,49,50,52,58,60,62,64], but only 3 studies evaluated SABA therapy versus placebo [66,67,74]. The 3 SABA studies were all 12 weeks in length and changes in exacerbation frequency for studies shorter than 24 weeks in duration are not considered clinically meaningful.
Other outcome variables
Among the other outcome variables there were insufficient SABA studies for indirect comparisons. The number of SABA studies for each variable was dyspnea (1), use of rescue medications (1), tremor (2), sixminute walking test (2), CDRQ (4, but only 1 with sufficient numerical information), and SGRQ (1).
The goal of this review was to complete a meta-analysis of published randomized clinical trials comparing LABAs and SABAs for maintenance treatment in COPD. Unfortunately, only a single study was found preventing the completion of a direct meta-analytic comparison. The single study was a 3-week randomized, double blind crossover trial comparing the addition of formoterol or salbutamol to ipratropium [16]. The primary outcome variable, peak expiratory flow, as well as post-dose FEV1 and the SGRQ symptom score improved significantly more during the formoterol/ipratropium treatment period than the salbutamol treatment period. There were no significant differences on SGRQ total, activity, or impacts sores, exacerbation rates, rescue medication use, or adverse events. The single RCT directly comparing SABA versus LABA found better outcomes for adding LABA to ipratropium than SABA to ipratropium
The direct meta-analytic comparison was not possible due to the lack of studies, so the possibility of an indirect comparison was examined. Indirect comparisons meta-analyses have a greater potential to produce biased results due to uncontrolled differences between patients or procedures in the different studies [78]. However, there was an insufficient number of SABA studies of two or more weeks in duration, with a placebo or ipratropium comparator, and with a relevant outcome variable reported with sufficient detail to allow for even an indirect meta-analysis. Further efforts to increase the number of SABA papers (such as including non-English publications, contacting authors to get variances or numeric estimates, adding the most recent publications) may have allowed an indirect meta-analysis on one or more outcome variables to be completed, but it is unlikely to yield particularly relevant information. In addition to the limitations of indirect comparisons, the SABA treatments were not used in any trials longer than 12 weeks rendering any findings for maintenance outcomes suspect. Because the goal of this research was to compare LABAs versus SABAs for use as maintenance therapy for COPD; we included only studies with duration of 2 weeks or longer. This restriction eliminated many of the studies of SABAs identified in the initial literature search, which were only 2- or 3-day studies.
The GOLD treatment guidelines for COPD recommend the use of long-acting bronchodilators (including LABAs) because they are effective and convenient [6]. Due to their longer duration of action, LABAs can control COPD symptoms throughout the night, whereas SABAs would lose effectiveness. In this review, we did not find any data supporting the use of SABAs for maintenance therapy. The single RCT that compared adding a LABA (formoterol) or a SABA (albuterol) to ipratropium, found better airflow outcomes for the LABA treatment [16].
LABAs have been studied extensively as maintenance therapies in patients with COPD and have long-term safety and efficacy evidence. Although many patients with COPD are only treated with SABAs in usual clinical care, there is an absence of empirical support for the use of SABAs as maintenance therapy. This review supports the current evidence-based guidelines for COPD, which recommend the preferential use of LABAs for maintenance treatment of COPD and reserves the use of SABAs for rescue treatment.
Funding for this study was provided by Sunovion Pharmaceuticals Inc. Technical writing support was provided by Michael Stensland of Agile Outcomes Research Inc, Rochester, Minnesota, USA.



 Download    pdf version of this article


Figures at a glance

Figure 1
Select your language of interest to view the total content in your interested language
Share This Article
About JPRM
Download Journal Home
Download Editorial Board Members
Download Current Issue
Download Previous Issue
Download Archive
Download Instructions for Authors
Download Submit Manuscript
Download Contact Editorial Office
Article usage
  Total views: 161819
  [From(publication date):
December-2011- Nov 21, 2014]
  Breakdown by view type
  HTML page views : 158096
  PDF downloads :3723
Article Tools
Download Export citation
Download Share/Blog this article
Download Recommend to your Librarian
Special Features
Download Download PDF
Download Digital File
Download Listen Audio
Download Download Audio